Article details
Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO) has signed a binding agreement to acquire an additional 12% stake in ENAYAH, a leading medical products manufacturer, for SAR 45 million. This will increase SPIMACO's ownership from 51% to 63% upon completion, pending regulatory approvals including amending ENAYAH’s articles of association and obtaining competition authority clearance. The transaction is financed through SPIMACO’s own resources and aligns with its strategy to strengthen investments in the medical sector. ENAYAH specializes in single-use medical products and operates one of the region’s largest sterilization facilities, serving markets across Saudi Arabia, the GCC, MENA, and Europe.
This acquisition strengthens SPIMACO’s position in the medical manufacturing ecosystem, enhancing its integration with key national companies. For markets, the deal signals SPIMACO’s commitment to expanding its footprint in healthcare, which could bolster its long-term revenue prospects. However, the financial impact will only be reflected in SPIMACO’s financial statements from H2 2026, suggesting a medium-term growth narrative. Traders may monitor regulatory progress and potential stock price reactions post-approval.
For Gulf investors, the deal underscores Saudi Arabia’s push toward healthcare sector localization under Vision 2030. SPIMACO’s increased stake in ENAYAH could drive synergies in production and market access. Key watchpoints include the timeline for regulatory approvals, ENAYAH’s operational performance, and SPIMACO’s broader strategic moves in the medical industry.
